FUJIFILM Irvine Scientific | Digital Event

fujifilm

This Webinar Ran on Wednesday July 20, 2022 

Achieving Optimal Results for Cell Immunotherapy Bioprocessing with GMP Chemically Defined Media

Welcome to the FUJIFILM Irvine Scientific webinar, an exclusive event that will explore the benefits of using chemically-defined (CD) and GMP media for immunotherapy bioprocessing.

Focusing on scale-up, reliability, reproducibility, and selecting the right critical raw material supplier is key to move from pre-clinical phase to commercialization. This digital symposium will cover all of these and more, so don’t miss out and join us to:

  • Address the latest advanced cell culture processes in the immunotherapy field
  • Explore methods for optimal cell immunotherapy bioprocessing results through the scientifically driven selection of chemically defined and GMP media and reagents

Webinar Leader

rpbert newman

Robert Newman, PhD

Chief Scientific Officer

FUJIFILM Irvine Scientific

  • Understand the three key factors for product development and their impact on manufacturability
  • Identify how the PRIME-XV Cell CDM supports viable T cell expansion without the addition of serum under chemically defined conditions while maintaining cell functionality

This is a unique opportunity for Cell & Gene Therapy experts to be at the heart of the discussion and discover the potential of chemically defined serum-free cell culture media for T cell and CAR T cell expansion.

Registration for the Achieving Optimal Results for Cell Immunotherapy Bioprocessing with GMP Chemically Defined Media Digital Symposium is Now Closed

About FUJIFILM Irvine Scientific:

fujifilm

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. We provide unrivaled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and bioproduction for commercial manufacturing of biotherapeutics and vaccines.

www.irvinesci.com